Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT06910358 is registered in ClinicalTrials.gov with Disc Medicine, Inc as lead sponsor.

NCT NCT06910358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06910358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Lead sponsor
Disc Medicine, Inc
Phase
Phase 3
Overall status
Completed
Start date
April 4, 2025
Completion date
September 8, 2026
Enrollment
183 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria (epp), x-linked protoporphyria (xlp)